Search - tctmd.com

Displaying 841 - 860 of 891

Sort: Relevancy | Date

Presentation TCT 2012

Technology and Procedural Changes

Presenter: Eberhard Grube

October 22, 2012

Presentation TCT 2012

TCT-111: First-in-Man Experience with a Two-Part Exchangeable Leaflet Bioprosthetic Valve

Presenter: Lars Svensson

October 22, 2012

Presentation TCT 2012

TCT-110: First Experience with a Novel Anatomically Adapted Percutaneous Heart Valve for the Tricuspid Position

Presenter: Desiree Pott

October 22, 2012

Presentation TCT 2012

TCT-108: Performance and Safety of the TRUE Dilatation Balloon Valvuloplasty Catheter for Aortic Balloon Valvuloplasty in Patients Undergoing TAVR

Presenter: Felix Woitek

October 22, 2012

Presentation TCT 2012

TAVR Use Patterns on the European Continent: Growth, Penetration, and Reimbursement

Presenter: Nicolo Piazza

October 22, 2012

Presentation TCT 2012

Stroke Risk After TAVR: Results from a Large Meta-analysis

Presenter: Raimund Erbel

October 22, 2012

Presentation TCT 2012

STACCATO Revisited: Reflections and Take-home Messages

Presenter: Leif Thuesen

October 22, 2012

Presentation TCT 2012

Severe COPD and Aortic Stenosis: Screening Evaluations and Management Considerations

Presenter: Vinod Thourani

October 22, 2012

Presentation TCT 2012

Reduces Paravalvular Regurgitation

Presenter: Benoit Daneault

October 22, 2012

Presentation TCT 2012

Presentation

Presenter: Isaac George

October 22, 2012

Presentation TCT 2012

Pioneer and Interventional Perspectives

Presenter: Alain Cribier

October 22, 2012

Presentation TCT 2012

Paravalvular Regurgitation as a Strong Predictor of Post-TAVR Mortality

Presenter: Susheel Kodali

October 22, 2012

Presentation TCT 2012

New Pacemakers After TAVR: Frequency, Predictors, Clinical Outcomes, and Guidelines on “When to Treat”

Presenter: Jeffrey Popma

October 22, 2012

Presentation TCT 2012

New Left Bundle Branch Block Is an Independent Predictor of Mortality After TAVR

Presenter: Patrick Houthuizen

October 22, 2012

Presentation TCT 2012

New Data from the PARTNER Continued Access (Non-randomized): Transfemoral Outcomes After TAVR

Presenter: Susheel Kodali

October 22, 2012

Presentation TCT 2012

New Data from PARTNER Continued Access (Non-randomized): Transapical Outcomes After TAVR

Presenter: Todd Dewey

October 22, 2012

Presentation TCT 2012

My Five Most Vexing Clinical Management Dilemmas in Aortic Stenosis Patients: What Is NOT KNOWN!

Presenter: Allan Schwartz

October 22, 2012

Presentation TCT 2012

My Criteria for Selecting Transapical TAVR (vs. Transfemoral TAVR or Open Surgery)

Presenter: Rudiger Lange

October 22, 2012

Presentation TCT 2012

Moderate or Severe Mitral Regurgitation and Aortic Stenosis: Surgery or TAVR?

Presenter: John Webb

October 22, 2012

Presentation TCT 2012

Intentional Risk “Drift” vs. Refinement in Risk Assessment: Data from SOURCE and Personal Experiences

Presenter: Martyn Thomas

October 22, 2012

Advertisement

Technology and Procedural Changes

TCT-111: First-in-Man Experience with a Two-Part Exchangeable Leaflet Bioprosthetic Valve

TCT-110: First Experience with a Novel Anatomically Adapted Percutaneous Heart Valve for the Tricuspid Position

TCT-108: Performance and Safety of the TRUE Dilatation Balloon Valvuloplasty Catheter for Aortic Balloon Valvuloplasty in Patients Undergoing TAVR

TAVR Use Patterns on the European Continent: Growth, Penetration, and Reimbursement

Stroke Risk After TAVR: Results from a Large Meta-analysis

STACCATO Revisited: Reflections and Take-home Messages

Severe COPD and Aortic Stenosis: Screening Evaluations and Management Considerations

Reduces Paravalvular Regurgitation

Presentation

Pioneer and Interventional Perspectives

Paravalvular Regurgitation as a Strong Predictor of Post-TAVR Mortality

New Pacemakers After TAVR: Frequency, Predictors, Clinical Outcomes, and Guidelines on “When to Treat”

New Left Bundle Branch Block Is an Independent Predictor of Mortality After TAVR

New Data from the PARTNER Continued Access (Non-randomized): Transfemoral Outcomes After TAVR

New Data from PARTNER Continued Access (Non-randomized): Transapical Outcomes After TAVR

My Five Most Vexing Clinical Management Dilemmas in Aortic Stenosis Patients: What Is NOT KNOWN!

My Criteria for Selecting Transapical TAVR (vs. Transfemoral TAVR or Open Surgery)

Moderate or Severe Mitral Regurgitation and Aortic Stenosis: Surgery or TAVR?

Intentional Risk “Drift” vs. Refinement in Risk Assessment: Data from SOURCE and Personal Experiences

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content